Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 8NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Immunotherapy, Active × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00098917 2008-01-28

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡